Birth control

CHC Releases First Black Birthing Initiative Impact Report

Retrieved on: 
Tuesday, April 30, 2024
Mortality, BBI, Health equity, Pregnancy, CHC, Health, Black, Mental health, Food, Death, Birth control

ALEXANDRIA, Va., April 30, 2024 /PRNewswire-PRWeb/ -- In honor of Black Maternal Health Week and National Minority Health Month in April and gearing up for National Women's Health Week in May, CHC: Creating Healthier Communities released the Black Birthing Initiative's first impact report.

Key Points: 
  • CHC's 3-year Black Birthing Initiative, funded by Elevance Health Foundation, is celebrating lives impacted by the initiative, which aims to improve the standard of care and strengthen the care ecosystem for Black women and birthing people.
  • "I have been proud and humbled to watch as the Black Birthing Initiative has grown from an ambitious concept on paper to a thriving initiative that has a daily impact on the lives of over 360 Black birthing people and families," said Valerie L. Rochester, chief health equity officer at CHC.
  • Through funding from Elevance Health Foundation, CHC launched the three-year Black Birthing Initiative in January 2022 to address the maternal health crisis .
  • "I have been proud and humbled to watch as the Black Birthing Initiative has grown from an ambitious concept on paper to a thriving initiative that has a daily impact on the lives of over 360 Black birthing people and families," said Valerie L. Rochester, chief health equity officer at CHC.

Health-E Commerce® shares 5 ways to use FSA or HSA funds to support women's health

Retrieved on: 
Monday, April 29, 2024
Inflammation, Stroke, Risk, Woman, Pregnancy, Health, Diabetes, Women's health, Fertility, Dysmenorrhea, Thyroid disease, Obesity, FSA, Mental health, Commerce, HSA, Oura, Sleep, Breast cancer, Birth control

DALLAS, April 29, 2024 /PRNewswire-PRWeb/ -- The hormonal changes that women experience throughout their lives put them at increased risk for serious or chronic health conditions like diabetes, stroke, obesity, and even breast cancer. Fortunately, managing everyday health can go a long way toward preventing the onset of these conditions. Now, as Women's Health Month kicks off, Health-E Commerce®, parent brand to FSA Store® and HSA Store®, is educating women who are enrolled in a flexible spending account (FSA) or health savings account (HSA) about how they can protect their health and manage the effects of hormonal changes – while also saving money by using their tax-free healthcare funds.

Key Points: 
  • There are numerous products and services available to support women on their health journeys.
  • FSA Store and HSA Store are proud to offer a wide variety of women's health products and a convenient, guaranteed-eligible shopping experience.
  • FSA Store and HSA Store are proud to offer a wide variety of women's health products and a convenient, guaranteed-eligible shopping experience."
  • To learn more about using tax-free funds to support women's health, visit the searchable eligibility lists at FSA Store or HSA Store .

LEGACY RANKS BEST AND WORST US STATES FOR SPERM HEALTH, LEVERAGING PROPRIETARY DATABASE

Retrieved on: 
Monday, April 29, 2024
Environment, Freezing, Health, PFAS, Science, Body composition, Interview, Diet, Birth control

Additionally, states with lower scores in other health metrics (such as air quality or access to healthcare) also rank lower for sperm health.

Key Points: 
  • Additionally, states with lower scores in other health metrics (such as air quality or access to healthcare) also rank lower for sperm health.
  • "The environment will continue to impact sperm, and sperm health naturally declines with age.
  • Legacy experts hosted a webinar on everyday chemical exposures and how to protect your sperm health.
  • For the complete report on the best and worst states for sperm health, visit https://www.givelegacy.com/the-united-states-of-sperm-quality/ .

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Saturday, April 27, 2024
Use, Polycystic ovary syndrome, Ovarian reserve, PCOS, WHO, Hormone, Danaher Corporation, Primary ovarian insufficiency, Health, World Health Organization, Woman, Infertility, Anti-Müllerian hormone, Health care, AMH, Fertility, Table, Intelligence, IVF, Bio-Rad Laboratories, Privacy, Thermo Fisher Scientific, Diagnosis, POC, Growth, Birth control

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.

Key Points: 
  • Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.
  • A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market.
  • "Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures"

Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Saturday, April 27, 2024
Use, Polycystic ovary syndrome, Ovarian reserve, PCOS, WHO, Hormone, Danaher Corporation, Primary ovarian insufficiency, Health, World Health Organization, Woman, Infertility, Anti-Müllerian hormone, Health care, AMH, Fertility, Table, Intelligence, IVF, Bio-Rad Laboratories, Privacy, Thermo Fisher Scientific, Diagnosis, POC, Growth, Birth control

Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.

Key Points: 
  • Anti-mullerian hormone (AMH) tests are critical in assessing a woman's remaining egg count, potential fertility, and the health of her ovaries.
  • A key tool in identifying PCOS is the Anti-Müllerian hormone (AMH) test, which measures the levels of AMH produced by ovarian follicles.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Anti-Mullerian Hormone Test Market.
  • "Dive into the Anti-Mullerian Hormone Test Market Landscape: Explore 195 Pages of Insights, 368 Tables, and 24 Figures"

Truveta delivers largest and most complete mother and child EHR dataset to advance healthcare

Retrieved on: 
Thursday, April 25, 2024
Mortality, Pregnancy, Dermatitis, HIPAA, Bias, Safety, Woman, Risk, Hospital, Certification, Policy, Health, EHR, Health care, MD, Research, ISO, Vaccine, PHI, Human, Comparable, Data, Patient, Privacy, Category, Physician, Gestational age, Mother, Child, Death, Asthma, SDOH, Birth control

Healthcare research has long been challenged with understanding maternal and pediatric health outcomes, often hindered by fragmented data sources and privacy concerns.

Key Points: 
  • Healthcare research has long been challenged with understanding maternal and pediatric health outcomes, often hindered by fragmented data sources and privacy concerns.
  • Now available in Truveta Data, Truveta offers more than one million mother-child pairs, the largest mother-child EHR dataset available today.
  • Truveta delivers regulatory-grade EHR data, including clinician notes and images, linked with claims, social drivers of health (SDOH), and mortality data, providing in-depth insights into patient care.
  • With access to over five years of longitudinal patient data, Truveta offers unparalleled depth and breadth for healthcare research.

Aeroflow Health Celebrates the Success of Nebraska’s Passage of Bill LB1215, Featuring Provisions to Include Access to Products & Services for Expecting and New Mothers

Retrieved on: 
Monday, April 22, 2024
Education, Health, Medicaid, Infant, Consultant, Patient, Legislation, CSO, Mother, Lactation, Birth control

Additionally, the law provides new mothers with ten visits with lactation consultants, starting no later than January 1, 2025.

Key Points: 
  • Additionally, the law provides new mothers with ten visits with lactation consultants, starting no later than January 1, 2025.
  • It's Aeroflow Health’s goal to ensure these mothers have access to the very best medical equipment to improve, and support, these mothers’ breastfeeding and postpartum health journeys.
  • With access to breast pumps and lactation services, mothers in Nebraska can get the education, clinical advice and support they need.
  • For more information about Aeroflow Health and their commitment to improving healthcare access and outcomes, visit https://aeroflowhealth.com/ .

3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024

Retrieved on: 
Friday, April 19, 2024
Pain, Attention, Hormone, IUD, Safety, Woman, Birth control

MANSFIELD, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- 3Daughters , Inc., a clinical development company fueling evolutionary healthcare for women, was voted the “Startup of Year” by top life science investors and venture capitalists at the 2024 BioLabs Investor Day that took place in Philadelphia on April 16, 2024.

Key Points: 
  • MANSFIELD, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- 3Daughters , Inc., a clinical development company fueling evolutionary healthcare for women, was voted the “Startup of Year” by top life science investors and venture capitalists at the 2024 BioLabs Investor Day that took place in Philadelphia on April 16, 2024.
  • BioLabs Investor Day events are carefully curated, invite-only pitch events where top startups are connected directly with major investors from across the eastern seaboard.
  • Out of 78 applications submitted, 3Daughters was one of 15 companies selected to pitch at the event.
  • Following a competitive pitch process, participating investors anonymously selected 3Daughters as the “Startup of The Year” for 2024.

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Retrieved on: 
Thursday, April 18, 2024
Șaeș, Cancer, Safety, Woman, Month, Group 2, HPV, Aes, APOLLO, Immune system, Autoimmunity, Ageing, Birth control

Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the placebo group.

Key Points: 
  • Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the placebo group.
  • “This was our first in-human, dose-ranging trial of VTP-200 in women with hrHPV-associated low-grade cervical lesions, who currently don’t have any treatment option until progression to high-grade lesions,” said Bill Enright, Chief Executive Officer of Barinthus Bio.
  • “However, these differences compared to placebo were not statistically significant given that the trial was not powered for individual dose group comparisons.
  • Further analyses are ongoing, mostly focusing on immunological responses and we plan to share the detailed results in due course.”

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

Retrieved on: 
Thursday, April 18, 2024
Congress, FDA, Woman, Infertility, Health, Research, White, Federation, TMSC, Birth control

Further, Lee-Sepsick is raising awareness of Femasys and the status of its reproductive products in light of the recently announced women’s health initiative from the White House.

Key Points: 
  • Further, Lee-Sepsick is raising awareness of Femasys and the status of its reproductive products in light of the recently announced women’s health initiative from the White House.
  • “Women’s health remain vastly underserved and underfunded but we are encouraged by the interest our solutions have received during recent meetings with members of Congress,” remarked Lee-Sepsick.
  • It has four commercially available products: FemaSeed® – FDA-cleared, intratubal insemination, FemVue® – contrast-generating device, FemCath® – selective delivery catheter, and FemCerv® – endocervical tissue sampler.
  • Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure.